CHICAGO, IL--(MARKET WIRE)--Jun 3, 2007 -- Novacea, Inc. (NasdaqGM:NOVC - News) today announced that clinical investigators will present two posters at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Final results from Novacea’s Phase 1/2 trial of Asentar(TM) (DN-101) in combination with Taxotere® [docetaxel (75 mg/m2 every three weeks)] in patients with non-small-cell lung cancer (NSCLC) will be presented by Dr. Howard J. West from the Swedish Cancer Institute in Seattle, WA. The second poster will provide data from the Novacea’s ASCENT trial on C-reactive protein as a prognostic marker in men with androgen-independent prostate cancer (AIPC) and will be presented by Drs. Julie Graff and Tomasz Beer from Oregon Health & Sciences University in Portland, OR.
